An Multicenter, Randomized Double-blind, Controlled Clinical Study of Nimotuzumab in Combined With First-line Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Squamous Cell Carcinoma
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Cisplatin (Primary) ; Nimotuzumab (Primary) ; Paclitaxel (Primary)
- Indications Cervical cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Biotech Pharmaceutical
- 22 Jan 2025 New trial record